Valderm
Valrubicin is a new, patented and well-documented compound from Valderm. The product offers pharmacetutical therapy for hyperproliferative skin diseases, such as psoriasis and similar.
Presently, there is no permanent cure for psoriasis, but a wide range of topical, systemic, and recently biological treatments are available for the management of the condition. The world market for psoriasis therapy is currently 1 billion USD annually.
Valrubicin is a much needed product for patients who will not benefit from strong therapy and who do not benefit from other milder therapies available on the market. Valderm's product has made clinical proof-of-concept in terms of antiproliferative effects and the cosmetic formula enabling penetration of target cells on animals.
The development of Valrubicin and Valderm's market situation leave room for partnerships with moderately sized pharmaceutical companies to collaborate on the final phases of completion.
web: www.valderm.dk
For further information, please contact
Ole Bitsch-Jensen, Investment Manager
obj@seedcapital.dk
Phone: +45 39179410